Chesapeake Partners Management’s Teva Pharmaceuticals TEVA Stock Holding History

Chesapeake Partners Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-750,000	Closed	-$49.2M	–	79
2015 Q4	$49.2M	Hold	750,000	–	–	2.75%	7
2015 Q3	$42.3M	Hold	750,000	–	–	2.21%	9
2015 Q2	$44.3M	Buy	750,000 +500,000	+200%	+$30.8M	1.7%	14
2015 Q1	$15.6M	Hold	250,000	–	–	0.72%	52
2014 Q4	$14.4M	Sell	250,000 -1,000,000	-80%	-$55.7M	0.55%	64
2014 Q3	$67.2M	Hold	1,250,000	–	–	2.48%	5
2014 Q2	$65.5M	Hold	1,250,000	–	–	1.98%	10
2014 Q1	$66M	Buy	+1,250,000	New	+$57.8M	2.56%	5

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Chesapeake Partners Management's TEVA Position: Q2 2016 in Review

Chesapeake Partners Management reduced its Teva Pharmaceuticals (TEVA) stake by 46% in Q2 2016, selling an estimated $18.1M and leaving 401,692 shares worth $20.2M. The position accounts for 3.02% of the portfolio, ranked #12.

Chesapeake Partners Management first reported a position in TEVA in Q2 2015 and has held it in 5 quarters since. The position peaked at $39.7M in Q1 2016. 813 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

Chesapeake Partners Management held 401,692 shares of Teva Pharmaceuticals worth $20.2M as of Q2 2016.
Chesapeake Partners Management sold 340,002 Teva Pharmaceuticals shares in Q2 2016, an estimated $18.1M.
Teva Pharmaceuticals made up 3.02% of Chesapeake Partners Management's portfolio in Q2 2016, its #12 holding.
Chesapeake Partners Management first reported a position in Teva Pharmaceuticals in Q2 2015 and has held it in 5 quarters since.
Chesapeake Partners Management's Teva Pharmaceuticals position peaked at $39.7M in Q1 2016.
813 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Chesapeake Partners Management's 13F filing for Q2 2016, filed 15 Aug 2016.